Xifaxan (Rifaximin) Patent Expiration, LOE Window & CMS Spending

Xifaxan (Rifaximin) by Bausch Health: FDA Orange Book core substance LOE 2027-09-02 (last listed 2029-10-02), 1 AB generics, $1.57B 2024 CMS Part D & Medicaid spend, and 13 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN021361 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-09-02
Last Listed Patent or Exclusivity Date2029-10-02
Orange Book Patents (*PED Extensions)19 patents (0 *PED)
Active AB-Rated Generic Competitors1
2024 CMS Total Public Spend$1.57B
2024 Medicare Part D Spend$1.16B
2024 Medicaid Spend$412.0M
Reported Wholesale Price Change (CA SB 17)13 WAC filings (max 27.7% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.